MolDX: Molecular Testing for Identification and Management of Hereditary Transthyretin Amyloidosis

Coverage is allowed for molecular testing to evaluate or manage suspected hereditary transthyretin amyloidosis (hATTR) when patients have a clinical diagnosis of ATTR, cardiac features suggestive of ATTR‑cardiomyopathy (with modifiers such as African ancestry, first‑degree affected relative, or additional guideline features), or progressive sensorimotor/autonomic neuropathy with relevant family history or additional guideline features. Tests must be clinically actionable (used to guide treatment), include validated minimum gene/variant content, have completed a technical assessment, and patients must be offered pre‑test counseling; tests containing unvalidated or unclear genetic content or lacking TA are not covered.

"Molecular diagnostic testing for hereditary transthyretin amyloidosis (hATTR) is covered when the patient has a clinical diagnosis of ATTR."

Sign up to see full coverage criteria, indications, and limitations.